• Anna M Schneider, Robert W Regenhardt, Adam A Dmytriw, Aman B Patel, Joshua Adam Hirsch, and Alastair M Buchan.
• Acute Stroke Programme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
• J. Neurol. Neurosurg. Psychiatr. 2023 Apr 1; 94 (4): 267271267-271.

AbstractDespite advances in clinical diagnosis and increasing numbers of patients eligible for revascularisation, ischaemic stroke remains a significant public health concern accounting for 3.3 million deaths annually. In addition to recanalisation therapy, patient outcomes could be improved through cerebroprotection, but all translational attempts have remained unsuccessful. In this narrative review, we discuss potential reasons for those failures. We then outline the diverse, multicellular effects of ischaemic stroke and the complex temporal sequences of the pathophysiological cascade during and following ischaemia, reperfusion, and recovery. This evidence is linked with findings from prior cerebroprotective trials and interpreted for the modern endovascular era. Future cerebroprotective agents that are multimodal and multicellular, promoting cellular and metabolic health to different targets at time points that are most responsive to treatment, might prove more successful.© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

11 keywords...

hide…